Overview

Absorption of Brimonidine Ophthalmic Solution in the Aqueous Humor of Cataract Patients

Status:
Completed
Trial end date:
2005-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to obtain and assay human aqueous samples following pre-operative dosing with 0.1% Brimonidine Purite™ (pH 7.8) or with 0.15% Brimonidine Purite® (pH 7.2) from patients undergoing routine cataract surgery in order to evaluate the aqueous concentration of the two formulations.Study hypothesis: The aqueous humor concentration 45 minutes following dosing of 0.1% Brimonidine Purite™ (pH 7.8) is comparable with 0.15% Brimonidine Purite® (pH 7.2)
Phase:
N/A
Details
Lead Sponsor:
Indiana University School of Medicine
Collaborator:
Allergan
Treatments:
Brimonidine Tartrate
Ophthalmic Solutions